Investors
Click here for Proxy Materials and Annual Meeting InformationAlnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi; a discovery that enables the creation of a broad new class of human therapeutics. Using RNAi, Alnylam has built a product platform to develop a deep pipeline of drug products to treat a
More >>Latest News
02/02/12
Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2011 Financial Results| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 2, 2012--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi
therapeutics company, today announced that it will report financial
results for the fourth quarter and year ending December 31, 2011 on
Thursday, February 9, 2012, after the U.S. financial markets close.
Management will provide an update on the company, discuss fourth quarter
and year-end 2011 results, and discuss expectations for th... |
|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
Print Page
E-mail Page
RSS Feeds
E-mail Alerts
IR Contacts
Financial Tear Sheet
